{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"Number of patients experienced DLT in each cohort","groups":[{"id":"OG000","title":"Cohort 1(30 mg/m2, BID, 5days/wk)/Phase I"},{"id":"OG001","title":"Cohort 2(45 mg/m2, BID, 5days/wk)/Phase I"},{"id":"OG002","title":"Cohort 3(45 mg/m2, BID, 7days/wk)/Phase I"},{"id":"OG003","title":"Cohort 4(60 mg/m2, BID, 7days/wk)/Phase I"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From the Date of PCI-24781 first administration to Cycle 2 Day 1","title":"Phase I (Dose Escalation Phase): MTD and DLTs of PCI-24781 Administered Twice Daily (BID) Measure: Disease Response","type":"PRIMARY","unitOfMeasure":"participants"}